Literature DB >> 18098275

Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.

Jordi Clarimón1, Javier Pagonabarraga, Coro Paisán-Ruíz, Antonia Campolongo, Berta Pascual-Sedano, José-Félix Martí-Massó, Andrew B Singleton, Jaime Kulisevsky.   

Abstract

Tremor dominant parkinsonism (TDP) is characterized by initial prominent resting and action tremor, mild parkinsonism, unpredictable response to medication, and a better prognosis than idiopathic Parkinson's disease (PD). We report on clinical features and longitudinal course of 26 patients suffering from TDP. Mean disease duration was 6.5 +/- 3 years, 61.5% of patients had a positive family history of tremor, 73% did not need drug treatment, performance of 123I-Ioflupane SPECT showed reduced striatal tracer uptake in 65.4% of patients, and odor identification testing was pathologic in all the patients tested (n = 22). Co-occurrence of action and resting tremor were the most annoying and disabling symptoms in all the patients, whereas rigidity and/or bradykinesia were clinically irrelevant in most of them. We also sequenced the full coding region of the Leucine-rich repeat kinase 2 gene (LRRK2) in all patients. We found a novel Val2390Met mutation that was not found in 864 chromosomes. Our results suggest a broader clinical heterogeneity related to LRRK2 mutations and points towards TDP as a subtype within the spectrum of PD, in which disabling tremor but otherwise mild parkinsonian signs and a better prognosis are the main characteristics. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18098275     DOI: 10.1002/mds.21771

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

1.  Phasic muscle activity in sleep and clinical features of Parkinson disease.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Sophia A Greer; Jorge J Juncos; David B Rye
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

2.  Motor subtype changes in early Parkinson's disease.

Authors:  Robert S Eisinger; Christopher W Hess; Daniel Martinez-Ramirez; Leonardo Almeida; Kelly D Foote; Michael S Okun; Aysegul Gunduz
Journal:  Parkinsonism Relat Disord       Date:  2017-07-21       Impact factor: 4.891

3.  Parkinson's disease motor subtype changes during 20 years of follow-up.

Authors:  Robert S Eisinger; Daniel Martinez-Ramirez; Adolfo Ramirez-Zamora; Christopher W Hess; Leonardo Almeida; Michael S Okun; Aysegul Gunduz
Journal:  Parkinsonism Relat Disord       Date:  2019-05-19       Impact factor: 4.891

4.  Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Authors:  Valtteri Kaasinen; Maija Kinos; Juho Joutsa; Marko Seppänen; Tommi Noponen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

5.  Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism.

Authors:  Takuya Konno; Owen A Ross; Robert E Wharen; Ryan J Uitti; Zbigniew K Wszolek
Journal:  Neurol Neurochir Pol       Date:  2016-06-24       Impact factor: 1.621

6.  Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Miguel Verbitsky; Sergey Kisselev; Barbara M Ross; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Elise Caccappolo; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  Arch Neurol       Date:  2009-12

Review 7.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 8.  Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

Authors:  Saskia Biskup; Andrew B West
Journal:  Biochim Biophys Acta       Date:  2008-10-10

Review 9.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

Review 10.  The motor prodromes of parkinson's disease: from bedside observation to large-scale application.

Authors:  C Simonet; A Schrag; A J Lees; A J Noyce
Journal:  J Neurol       Date:  2019-12-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.